Skip to main content
Log in

PERK inhibitor, GSK2606414, ameliorates neuropathological damage, memory and motor functional impairments in cerebral ischemia via PERK/p-eIF2ɑ/ATF4/CHOP signaling

  • Original Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

The protein kinase R-like endoplasmic reticulum kinase/eukaryotic initiation factor 2ɑ (PERK/eIF2α), the branch of unfolded protein response (UPR), is responsible for transient arrest in translation to counter the enhanced levels of misfolded or unfolded proteins in the endoplasmic reticulum (ER) following any acute condition. In neurological disorders, overactivation of PERK-P/eIF2-P signaling, leads to a prolonged decline in global protein synthesis resulting in synaptic failure and neuronal death. Our study has shown, PERK/ATF4/CHOP pathway gets activated following cerebral ischemia in rats. We have further demonstrated, PERK inhibitor, GSK2606414 ameliorates ischemia induced neuronal damage by preventing additional neuronal loss, minimizing brain infarct, reducing brain edema, and preventing neurological symptoms from appearing. GSK2606414 was found to improve the neurobehavioral deficits and reduce the pyknotic neurons in ischemic rats. Also, it decreased glial activation and apoptotic protein mRNA expression while enhanced the synaptic protein mRNA expression in rat brain following cerebral ischemia. In conclusion, our findings suggest that PERK/ATF4/CHOP activation play a vital role in cerebral ischemia. Thus, PERK inhibitor, GSK2606414 might be a potential neuroprotective agent in cerebral ischemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Data availability

Data will be made available on reasonable request.

Abbreviations

ATF4:

Activating transcription factor 4

ATF6:

Activating transcription factor 6

CHOP:

C/EBP homologous protein

EIF2AK3:

Eukaryotic translational initiation factor 2α kinase-3

IRE1:

Inositol requiring enzyme 1

ER:

Endoplasmic reticulum

MCAO:

Middle cerebral artery occlusion

PERK:

Protein kinase R-like endoplasmic reticulum kinase

MWM:

Morris water maze

NOR:

Novel object recognition

P-eIF2ɑ:

Phosphorylated eukaryotic initiation factor 2ɑ

SAH:

Subarachnoid hemorrhage

UPR:

Unfolded protein response

TTC:

2,3,5-triphenyl-tetrazolium chloride

IHC:

Immunohistochemistry

RT-PCR:

Real time polymerase chain reaction

References

Download references

Acknowledgements

The authors acknowledge the Department of Health Research (DHR), under the Ministry of Health and Family Welfare, Government of India for awarding the Young Scientist fellowship to Ms. Neha Dhir. Also, the authors gratefully appreciate GlaxoSmithKline (GSK) Pharmaceuticals Ltd. for providing the drug (GSK260414) to conduct this study. Authors also acknowledge PGIMER, Chandigarh, India for providing the facilities and resources to conduct this study.

Funding

The project was funded by the Department of Health Research (DHR), under the Ministry of Health and Family Welfare, Government of India. (Grant No. R 12014/18/2018-HR).

Author information

Authors and Affiliations

Authors

Contributions

Neha Dhir, Biksah Medhi and Ajay Prakash have designed the study protocol and experiments. Neha Dhir, Ashish Jain and Amit Raj Sharma performed the experimental and molecular experiments. Bishan Das Radotra helped in analysing histopathological data. All authors have analysed the data. Neha Dhir has written the manuscript. All authors have read, corrected and approved the manuscript.

Corresponding author

Correspondence to Bikash Medhi.

Ethics declarations

Ethical approval

The Institutional Animal Ethics Committee (IAEC) at the Postgraduate Institute of Medical Education and Research in Chandigarh, India, approved the study protocol. (IAEC Approval No. 93/IAEC/653).

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no conflicts of interest either financial or personal in this study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhir, N., Jain, A., Sharma, A.R. et al. PERK inhibitor, GSK2606414, ameliorates neuropathological damage, memory and motor functional impairments in cerebral ischemia via PERK/p-eIF2ɑ/ATF4/CHOP signaling. Metab Brain Dis 38, 1177–1192 (2023). https://doi.org/10.1007/s11011-023-01183-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-023-01183-w

Keywords

Navigation